

Special Issue

SARS-CoV-2 Variants Research and Ending the COVID-19 Pandemic

Message from the Guest Editors

Since the end of January 2020, the world has been experiencing a disastrous pandemic caused by a novel coronavirus, named SARS-CoV-2, first identified in Wuhan, China, and which rapidly spread worldwide. The pandemic has devastated healthcare systems, imposed strict national lockdown, and is responsible for over a million deaths across the world. The emergence of new and more infectious SARS-CoV-2 variants is raising concern, and vaccination may represent a primary tool to counteract the pandemic, virus spread, and mortality. In this Special Issue, we aim to cover all aspects related to SARS-CoV-2 variants, vaccines, and immune response. The goal is to provide an overview of the most relevant investigations related to SARS-CoV-2 and the COVID-19 pandemic.

Guest Editors

Dr. Claudia Maria Trombetta

Prof. Emanuele Montomoli

Dr. Serena Marchi

Deadline for manuscript submissions

closed (31 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/92644

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).